Natixis’s Spyre Therapeutics SYRE Stock Holding History

Natixis’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20,040	Closed	-$355K	–	1220
2025 Q2	$355K	Buy	+20,040	New	+$297K	﹤0.01%	745

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Natixis's SYRE Position: Q3 2025 in Review

Natixis sold out of Spyre Therapeutics (SYRE) in Q3 2025, closing a stake of 20,040 shares — an estimated $355K sold.

Natixis first reported a position in SYRE in Q2 2025 and held it in 1 quarter. The position peaked at $355K in Q2 2025. 137 funds tracked by Wall St. Rank hold SYRE as of Q3 2025.

Natixis reported no remaining Spyre Therapeutics position as of Q3 2025 after selling out during the quarter.
Natixis sold 20,040 Spyre Therapeutics shares in Q3 2025, an estimated $355K.
Natixis first reported a position in Spyre Therapeutics in Q2 2025 and held it in 1 quarter.
Natixis's Spyre Therapeutics position peaked at $355K in Q2 2025.
137 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2025.

Based on Natixis's 13F filing for Q3 2025, filed 14 Nov 2025.